Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 12 of 12

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Dose Limiting Toxicities	Up to 28 days	The patients who had DLT in dose escalation course.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Patients Who Had Grade 3 or Above Toxicities With the Three Attributions, 'DEFINITE', 'POSSIBLE','PROBABLE'	Up to 28 days	Part A and B Patients	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Half-life	Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+	all toxicity evaluable patients	hours	MEAN
PRIMARY	Time to Maximum Concentration (T Max)	Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+	All toxicity evaluable patients	hours	MEAN
PRIMARY	Maximum Concentration (C Max)	Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+	All toxicity evaluable patients	ug/ml	MEAN
PRIMARY	Area Under Curve (AUC)	Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+	All toxicity evaluable patients	hr*ug/ml	MEAN
PRIMARY	Clearance	Prior to, at the end of, and 2 hours after infusion on day 1 of cycles 1-2; days 4 & 8 of cycle 1; prior to and the end of infusion on day 15 of cycle 1; prior to start of infusion on day 15 of cycle 2; prior to start of infusion on day 1 of cycles 3+	All toxicity evaluable patients	ml/hr	MEAN
PRIMARY	Disease Control Rate (Part A)	Up to 4 months		participants	NUMBER
PRIMARY	Response (Complete Response or Partial Response) (Part B)	Up to 168 days		participants	NUMBER
SECONDARY	T-lymphocyte Saturation	Up to 28 days	All Eligible Patients	percent of T-lymphocyte Saturation	MEAN
SECONDARY	Total Soluble SEMA4D	Up to 28 days	All eligible patients	pg/mL	MEAN
SECONDARY	Immunogenicity of Pepinemab	Up to 3 years	The planned assays for ADA were unable to generate interpretable results due to limitations of the assay which resulted in higher levels of false positive results. These samples were re-run and only one confirmed positive result out of 81 samples, which was considered to be a true positive ADA. Even this one confirmed positive result had a negative titer, which further signifies a possible false positive or very low-level ADA. Therefore, results were determined to be unreliable and invalid.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03320330/outcomes

API reference For AI assistants